Financial Performance - The company's revenue for Q1 2023 was ¥876,697,159.06, representing a 39.72% increase compared to ¥627,481,511.98 in the same period last year[5] - Net profit attributable to shareholders decreased by 19.64% to ¥15,287,632.67 from ¥19,024,073.27 year-on-year[5] - Total operating revenue for Q1 2023 reached ¥876,697,159.06, an increase of 40% compared to ¥627,481,511.98 in the same period last year[22] - The net profit after deducting non-recurring gains and losses was ¥14,743,747.96, down 22.39% from ¥18,996,162.02 in the same period last year[5] - The net profit for Q1 2023 was CNY 18,898,654.75, a slight decrease from CNY 19,024,073.27 in Q1 2022, representing a decline of approximately 0.66%[24] - The total comprehensive income for Q1 2023 was CNY 18,898,654.75, slightly lower than CNY 19,024,073.27 in Q1 2022, reflecting a decrease of about 0.66%[25] - The operating profit for Q1 2023 was CNY 23,887,783.40, down from CNY 24,986,516.99 in the same period last year, reflecting a decrease of approximately 4.4%[24] Cash Flow and Liquidity - The net cash flow from operating activities improved by 65.75%, reaching -¥93,644,192.00, compared to -¥273,388,665.81 in the previous year[11] - The cash flow from operating activities showed a net outflow of CNY -93,644,192.00 in Q1 2023, an improvement from CNY -273,388,665.81 in Q1 2022[27] - The company's cash and cash equivalents decreased to ¥450,069,265.22 from ¥542,999,989.85 at the beginning of the year, a decline of approximately 17%[18] - The company reported a cash and cash equivalents balance of CNY 437,643,887.18 at the end of Q1 2023, down from CNY 465,103,994.99 at the end of Q1 2022[28] - The total cash inflow from financing activities in Q1 2023 was CNY 449,951,126.73, significantly higher than CNY 219,545,189.63 in Q1 2022, marking an increase of about 105%[27] - The company incurred a total cash outflow from investing activities of CNY 209,292,390.70 in Q1 2023, compared to CNY 13,487,863.80 in Q1 2022, indicating a substantial increase in investment expenditures[27] Assets and Liabilities - The total assets at the end of the reporting period increased by 6.92% to ¥4,203,580,541.74 from ¥3,931,417,218.63 at the end of the previous year[5] - The company's total assets reached ¥4,203,580,541.74, compared to ¥3,931,417,218.63 at the beginning of the year, reflecting a growth of about 6.9%[21] - Total liabilities increased to ¥2,357,970,678.47 from ¥2,113,011,215.54, a rise of approximately 11.6%[21] - Non-current assets totaled ¥1,139,835,964.67, up from ¥920,012,264.75, indicating a growth of about 23.9%[20] - Short-term borrowings increased to ¥1,326,629,126.56 from ¥1,198,109,033.37, reflecting a rise of approximately 10.7%[20] - Accounts receivable increased to ¥1,506,857,865.37 from ¥1,399,682,875.49, representing a growth of about 7.7%[18] - Inventory rose significantly to ¥573,796,527.21, up from ¥433,209,490.63, marking a 32.5% increase[19] Shareholder Information - The company reported a total of 16,930 common shareholders at the end of the reporting period[12] - Basic and diluted earnings per share for Q1 2023 were both CNY 0.07, compared to CNY 0.09 in Q1 2022, indicating a decrease of approximately 22.2%[25] Business Operations - The company introduced new product distribution projects, contributing to the significant revenue growth in Q1 2023[10] - The company is actively expanding its business through acquisitions of new chain pharmacies and improvements in pharmaceutical distribution sales collections[11] - The company received government subsidies amounting to ¥95,000.00, which were closely related to its normal business operations[7] Profitability Metrics - The weighted average return on equity decreased to 0.88% from 1.12% year-on-year[5] - The net profit margin for Q1 2023 is not explicitly stated but can be inferred from the increase in revenue and costs, indicating potential profitability improvements[22] - Total operating costs for Q1 2023 were ¥843,561,238.37, up from ¥599,973,598.18 in Q1 2022, reflecting a 40.5% increase[22] - The company reported a significant increase in cash received from other operating activities, amounting to CNY 53,316,489.89 in Q1 2023, compared to CNY 10,958,715.28 in Q1 2022, representing an increase of approximately 387%[27]
达嘉维康(301126) - 2023 Q1 - 季度财报